Incyte/INCY

$60.53

-0.09%
-
1D1W1MYTD1YMAX

About Incyte

Incyte Corporation is a biopharmaceutical company, which is focused on the discovery, development, and commercialization of therapeutics. The Company also conducts clinical development and commercial operations from its European headquarters in Morges, Switzerland and its other offices across Europe, as well as its Japanese office in Tokyo and its Canadian headquarters in Montreal. It operates in two therapeutic areas, One therapeutic area is Hematology/Oncology, which is comprised of Myeloproliferative Neoplasms and Graft-Versus-Host Disease, as well as solid tumors and hematologic malignancies. Its other therapeutic area is Inflammation and Autoimmunity, which includes its Dermatology commercial franchise. Its hematology and oncology franchise are comprised of four products, which are JAKAFI (ruxolitinib), MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab), PEMAZYRE (pemigatinib), ICLUSIG (ponatinib), and ZYNYZ (retifanlimab-dlwr), as well as numerous clinical development programs.

Ticker

INCY

Sector

Healthcare

Trading on

NASDAQ

Industry

Biotechnology & Drugs

CEO

Herve Hoppenot

Employees

2,524

Headquarters

Wilmington, United States

Incyte Metrics

BasicAdvanced
$13.6B
Market cap
22.92
P/E ratio
$2.64
EPS
0.66
Beta
-
Dividend rate

What the Analysts think about Incyte

Analyst Ratings

Majority rating from 22 analysts.
Buy

Price Targets

Average projection from 17 analysts.
24.78% upside
High $92.00
Low $61.00
$60.53
Current price
$75.53
Average price target

Incyte Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
19.83% profit margin
QuarterlyAnnual
Q4 23
QoQ growth
Revenue
$1.01B
10.26%
Net income
$201M
17.41%
Profit margin
19.83%
6.5%

Incyte Earnings Performance

Earnings per share (EPS)

Company profitability
Missed by 8.38%
QuarterlyAnnual
Q1 23
Q2 23
Q3 23
Q4 23
Q1 24
Actual
$0.37
$0.99
$1.10
$1.06
-
Expected
$0.76
$0.83
$1.02
$1.16
$0.87
Surprise
-51.02%
19.81%
7.44%
-8.38%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.

Upcoming events

Buy or sell Incyte stock

Buy or sell Incyte stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing